Yahoo Finance analysis indicates that Pfizer (PFE) stock is currently trading at $28.77, considered undervalued, with analysts issuing a "buy" rating and setting a 12-month price target of $32.72, implying a potential upside of approximately 14%. This bullish outlook is primarily driven by over 20% revenue growth from its oncology drug Padcev, and positive data from its GLP-1 obesity drug, which showed an average weight loss of 16% in Phase 2b clinical trials. Additionally, Pfizer's Q2 revenue reached $15 billion, with adjusted diluted EPS of 77 cents, and management raised the midpoint of its full-year revenue guidance by $500 million to $60.5 billion-$62.5 billion.